As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current ...

Newly approved drug Datroway, for which it has a partnership with Daiichi Sankyo, recorded revenues of $11 million in the quarter compared with $4 million in the first quarter, driven by ...

The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)’s focus on collaborative innovation.

The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)’s focus on collaborative innovation. This approval strengthens the company’s extensive oncology portfolio, which ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) reported Thursday first-quarter profit attributable to shareholders of 85.50 billion Japanese yen, up 0.1 percent from 85.38 ...

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in March 2019and DATROWAY®in July 2020, except in Japan where Daiichi Sankyo ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...